Silexion Therapeutics Corp 8-K

What Happened
Silexion Therapeutics Corp. announced adjustments to its public and private warrants following its previously announced 1-for-10 reverse share split. The company issued a Warrant Adjustment Notice effective after the close of trading on May 28, 2026 (reflected at open on May 29, 2026) and filed a Memorandum Amendment dated May 28, 2026 related to the reverse split. The adjustments were made under the original Warrant Agreement (Feb. 19, 2021) assigned to Silexion as part of the business combination completed Aug. 15, 2024.

Key Details

• Effective after market close on May 28, 2026 (reflected May 29, 2026): each pre-reverse-split warrant that purchased one share will instead be exercisable for 1/10th of a post-split ordinary share.
• The exercise price per whole post-reverse-split ordinary share is increased ten-fold to $15,525.00.
• The company will not issue fractional shares on exercise; fractional amounts will be rounded up at the level of brokers who are DTC participants, and holders must pay the full exercise price for the rounded whole shares.
• Warrant CUSIP remains G1281K 114 and the trading symbol remains “SLXNW.” A copy of the Warrant Adjustment Notice was filed as an exhibit to the 8-K.

Why It Matters
For warrant holders, the split changes the number of shares each warrant buys (fewer shares per warrant) while proportionally increasing the per-share exercise price so the economic terms remain adjusted for the share consolidation. The fractional-share rounding rule means some holders may be required to pay the full exercise price for a rounded-up whole share when exercising. Investors should check brokerage statements for updated warrant holdings and consult the Warrant Adjustment Notice or their broker/transfer agent for questions or to confirm how rounding and exercises will be handled.